228577-00-2

TZD18 is a novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.

TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 μM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes[1].

hPPARα: 0.028 μM (IC₅₀); hPPARγ: 0.057 μM (IC₅₀); PPARδ: >10 μM (IC₅₀)

[1] Guo Q, et al. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. DOI:10.1210/en.2003-1270